Trial
NCT01588314
Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Minnesota
Collaborators
Genzyme, a Sanofi Company
Condition
Fabry Disease
Intervention
Gabapentin
Why stopped
No patients were enrolled. No data \& no study results to report.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-29